PolyPid Competitors and Similar CompaniesClear all
PolyPid's competitors and similar companies include Adaptimmune.
 PolyPid PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API). |  Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. | |
Founding Date | Founding Date 2008 | Founding Date 2008 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Petah Tikva, IL HQ Summit, US | Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB |
Employees | Employees 57 | Employees 4007% decrease |
Valuation ($) | Valuation ($) 23.7 m | Valuation ($) 188.5 m |
Financial | ||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $178m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods $70k (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit $178m (FY, 2024) |
Net income | Net income ($34.2m) (FY, 2025) | Net income ($70.8m) (FY, 2024) |
Operating ⚠ | ||
Patent Applications | Patent Applications 49 (FY, 2017) | Patent Applications 69 (FY, 2016) |
Patents Issued | Patents Issued 104 (FY, 2017) | Patents Issued 173 (FY, 2016) |
Funding | ||
Total funding raised | Total funding raised $ 103.8m | Total funding raised $ 107.5m |
For sources of this data, please see the company profile
View Company Profiles
Adaptimmune
HQ
Philadelphia, US
Employees
400↓ 7% decrease
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
View company